Related Experiment Video
Updated: May 2, 2026
04:35
Saline Lavage for Sampling of the Canine Nasal Immune Microenvironment
Published on: December 27, 2024
1.2K
Lymphangiosarcoma in 12 dogs: a case series (1998-2013)
K M Curran1, C H C Halsey1,2, D R Worley1,3
1Flint Animal Cancer Center, Colorado State University, Fort Collins, CO, USA.
Veterinary and Comparative Oncology
|March 12, 2014
Summary
Lymphangiosarcoma (LAS) in dogs is rare, often presenting as masses. Multimodal therapy, including surgery, radiation, and chemotherapy, showed clinical improvement in canine LAS patients.
Area of Science:
- Veterinary Oncology
- Cancer Biology
Background:
- Lymphangiosarcoma (LAS) is a rare malignant neoplasm originating from lymphatic endothelium.
- Limited therapeutic information is available for canine LAS.
- Canine LAS often presents as masses or swelling in various body regions.
Purpose of the Study:
- To review therapeutic outcomes for canine lymphangiosarcoma.
- To evaluate the efficacy of different treatment modalities for canine LAS.
- To identify factors influencing survival in dogs with LAS.
Main Methods:
- Retrospective review of canine LAS histopathology diagnoses over 15 years.
- Analysis of treatment protocols, including palliative care, prednisone, chemotherapy, surgery, and multimodal therapy.
- Evaluation of survival times and recurrence rates based on treatment received.
Main Results:
- Twelve canine cases of LAS were identified.
- Dogs receiving multimodal therapies, particularly surgery combined with chemotherapy and/or radiation, demonstrated clinical improvement.
- Survival times varied significantly, with longer durations observed in dogs undergoing aggressive treatment protocols.
Conclusions:
- Multimodal therapy appears beneficial for managing canine lymphangiosarcoma.
- Early diagnosis via tissue biopsy is crucial for progressive, edematous lesions of unknown origin.
- Further research is warranted to optimize treatment strategies for canine LAS.
